Drug Trial Radar · NCT06088888
TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 2, 2024
Primary completion
Dec 31, 2027
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- M.D. Anderson Cancer Center
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Conditions
- Chronic Myelogenous Leukemia
Interventions
TGRX-678Drug
Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended dose for expansion (RDE)Time frame: Time Frame: At end of Dose Escalation part of study, an average of 1 year
- Safety profile (DLT)Time frame: Time Frame: DLT: collect during Cycle 1 (28 days)
- Safety profile (AEs/SAEs)Time frame: AE and SAE: through completion of the study, an average of 2 years
- Recommended phase II dose (RP2D)Time frame: At completion of the study, an average of 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.